TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00715663

Intervention type: DRUG
Intervention: biphasic insulin aspart 30
Description: No intervention is done. For study drug, start dose and frequency of administration to be prescribed by the physician as a result of normal clinical evaluation
Study: NCT02712593

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Niagen™ 100

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Niagen™ 300

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Niagen™ 1000

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT00687336

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Empirical Hp eradication
Description: Empirical Helicobacter pylori treatment initiated immediately after oral intake is resumed

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Eradication treatment guided by a positive test
Description: Eradication treatment given if there is at least one positive diagnostic test (URT, histological test, breath test or serology) for Helicobacter pylori.
Study: NCT02265081

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound
Description: pelvic floor ultrasound

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ultrasound
Description: pelvic floor ultrasound

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ultrasound
Description: pelvic floor ultrasound

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: uroflow-meter
Description: uroflow meter: measurement of passed urine volume

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: uroflow-meter
Description: uroflow meter: measurement of passed urine volume

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: uroflow-meter
Description: uroflow meter: measurement of passed urine volume
Study: NCT05075343

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Custom foot orthoses
Description: 3D printed custom foot orthoses (CFO) were designed by the same experimented podiatrist based on a detailed clinical and biomechanical examination and a 3D foot scan obtained for each participant. The degrees and types were adjusted at the CFO delivery according to each patient's comfort and tolerance.~The intervention period was 7weeks. The participants were taught to wear the CFO progressively during the first two weeks to allow for the lower limbs' muscles and structures to adjust to the CFO, and to wear the orthoses for the next 5 weeks, 7 days a week as often as they could.
Study: NCT05351645

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment
Description: Once per day for a 14-day trial period, participants in the Treatment group were assigned to read a first-person narrative about a past issue with suicidal thoughts or behaviors. These narratives each contained positive elements, such as providing details about how the author had overcome issues with suicide, suggesting that people with suicidal thought are not alone, or encouraging people with suicidal thoughts/behaviors to have hope.
Study: NCT02691351

Intervention type: OTHER
Intervention: Prospective Registry
Description: Survival and disease status follow-up at 1st primary treatment, 1st salvage treatment and 2nd salvage treatment~1. Regimen~2. Response Evaluation~3. SUSAR(Suspected, Unexpected, Serious, Adverse Reaction) collection
Study: NCT00624663

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivastigmine
Description: Administration 1 (A): 1 x 1.5 mg Exelon® Capsule (Novartis) + 1 x Placebo Capsule Administration 2 (B): 2 x 1.5 mg Exelon® Capsules (Novartis) Administration 3 (C): 2 x Placebo Capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivastigmine
Description: Administration 1 (A): 1 x 1.5 mg Exelon® Capsule (Novartis) + 1 x Placebo Capsule Administration 2 (B): 2 x 1.5 mg Exelon® Capsules (Novartis) Administration 3 (C): 2 x Placebo Capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rivastigmine
Description: Administration 1 (A): 1 x 1.5 mg Exelon® Capsule (Novartis) + 1 x Placebo Capsule Administration 2 (B): 2 x 1.5 mg Exelon® Capsules (Novartis) Administration 3 (C): 2 x Placebo Capsules
Study: NCT02238197

Intervention type: DRUG
Intervention: Atrovent® Inhalation Solution
Study: NCT03792217

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 1.3% NaOCl
Description: Endodontic irrigant

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 5.25% NaOCl
Description: Endodontic irrigant
Study: NCT01696318

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Support for the Family Health Team
Description: Participation in physical educator, dietitian and pharmacist in primary health care
Study: NCT00466674

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: reduced intensity conditioning
Description: reduced intensity conditioning for allogenic transplant
Study: NCT02781896

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: pacing catheter
Description: Rapid pacing during TAVI is required to ensure transient cardiac standstill while predilatation is performed and the valve is being positioned and deployed. In the right ventricular pacing arm, rapid pacing is provided by a standard right ventricular pacing catheter.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: valve delivery guidewire
Description: Rapid pacing during TAVI is required to ensure transient cardiac standstill while predilatation is performed and the valve is being positioned and deployed. In the Left ventricular pacing arm, rapid pacing is provided via the valve-delivery guidewire inserted into the left ventricle. The cathode of an external pacemaker is placed on the external end of the guidewire using an alligator clamp. The TAVI catheter provides the necessary insulation. The anode is attached directly to the subcutaneous tissue at the femoral entry site (also using an alligator clamp).
Study: NCT02186509

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hyperfractionated radiation therapy
Description: Undergo hyperfractionated radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic radiosurgery
Description: Undergo stereotactic radiosurgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisertib
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quality-of-life assessment
Description: Ancillary studies
Study: NCT01463293

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: B. lactis HN019
Description: Capsule containing 10 billion cfu B. lactis HN019 once a day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: B. lactis HN019
Description: Capsule containing 1 billion cfu B. lactis HN019 once a day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule containing no probiotic once a day
Study: NCT01949597

Intervention type: PROCEDURE
Intervention: laparoscopic surgery for deep endometriosis
Study: NCT02554630

Intervention type: OTHER
Intervention: Adjuvant
Description: Blood will be incubated, ex-vivo, with one of the adjuvant therapies or no adjuvant and then, using microfluidic techniques the immune genomic profile and the functional capacity of immune cells will be assessed.

Intervention type: OTHER
Intervention: Adjuvant
Description: Blood will be incubated, ex-vivo, with one of the adjuvant therapies or no adjuvant and then, using microfluidic techniques the immune genomic profile and the functional capacity of immune cells will be assessed.

Intervention type: OTHER
Intervention: Adjuvant
Description: Blood will be incubated, ex-vivo, with one of the adjuvant therapies or no adjuvant and then, using microfluidic techniques the immune genomic profile and the functional capacity of immune cells will be assessed.

Intervention type: OTHER
Intervention: Blood Collection
Description: Blood collection will be performed on all groups.

Intervention type: OTHER
Intervention: Blood Collection
Description: Blood collection will be performed on all groups.

Intervention type: OTHER
Intervention: Blood Collection
Description: Blood collection will be performed on all groups.
Study: NCT00210119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glivec
Study: NCT03184090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: palbociclib in combination with endocrine therapy (investigator's choice)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endocrine therapy (non IMP)
Description: Endocrine therapy (physician's choice based on prior administered agent including tamoxifen, exemestane, fulvestrant, anastrozole, or letrozole). Endocrine therapy must be different from previous treatment line.
Study: NCT06628752

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Deep brain stimulation
Description: Stimulation through a device implanted bilaterally into deep brain structures.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Deep brain stimulation
Description: Stimulation through a device implanted bilaterally into deep brain structures.
Study: NCT04712591

Intervention type: DIAGNOSTIC_TEST
Intervention: Auditory stimuli
Description: Auditory stimuli (passive, active perturbations)

Intervention type: DIAGNOSTIC_TEST
Intervention: Auditory stimuli
Description: Auditory stimuli (passive, active perturbations)
Study: NCT03374930

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Multiple rapid swallows test
Description: Multiple rapid swallows test consists in giving to patient 4 to 6 sips of 2 mL of water, with an interval less than 4 seconds between the different sips.
Study: NCT04450784

Intervention type: OTHER
Intervention: collection of the clinical and biological characteristics of secondary AMLs in children
Description: to record scientific and medical information on cases of secondary Acute Myeloid Leukemias that have occurred in France since 2013
Study: NCT02086084

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIV
Description: Standard care

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NIV
Description: Standard care

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ECCO2R
Description: Application of ECCO2R in addition to NIV
Study: NCT03598920

Intervention type: DEVICE
Intervention: AsspireAssist
Description: Endoscopic bariatric procedure using the AsspireAssist device

Intervention type: OTHER
Intervention: Nutritional consulting
Description: Nutritional consulting provided by a specialized consultant.
Study: NCT02774122

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CAABT
Description: CAABT was an innovative tinnitus intervention which based on neural science and cochlear plastic research and aimed to reprogram the central auditory system to neutralize the discordant responses of the dysfunctioning cochlea via acoustic beaming stimuli.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: masking therapy
Description: Masking intervention was a standard monophone tinnitus masking therapy.
Study: NCT05566834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minnelide
Description: at the MTD dose level established for monotherapy or combination to confirm safety. With a sample of 12 patients, the probability is \> 80% that a serious adverse event with at least a 16% incidence will be detected.
Study: NCT01747889

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electronic chest drainage system
Description: Patients in the intervention arm are connected to Thopaz, electronic drainage system immediately after closure of the chest, patients in the control group are connected to a traditional system. Chest tubes in both groups are then connected to suction of -20 cmH2O and maintained at that level until post-operative day #1.~On the morning of post-operative day #1, presence of air leak will be recorded on suction. Then, suction will be decreased to -8 cmH2O (so-called water seal). At that time, management of chest tube drainage and decision for chest tube removal will be dictated by clinical signs, symptoms, and surgeon preference following the standard clinical algorithm for post-operative care of general thoracic patients
Study: NCT01671072

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TissueGene-C
Description: TissueGene-C at 1.8 x 10\^7 cells

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Sodium chloride 0.9%, 3.5ml
Study: NCT00662662

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: The questionnaire contains 18 questions and is estimated to take approximately 10-15 minutes to complete.

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: The questionnaire contains 18 questions and is estimated to take approximately 10-15 minutes to complete.
Study: NCT02868567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dalfampridine
Description: Pill open label
Study: NCT02860000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisertib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisertib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Given IM

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT00209222

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: G-CSF
Description: growth factor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: growth factor

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: chemotherapy: R-CHOP
Description: immuno-chemotherapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: chemotherapy: R-CHOP
Description: immuno-chemotherapy
Study: NCT02141568

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical and Psychological treatment
Description: Medical and psychological treatment by the staff of the functional neurology clinic at Soroka UMC. This treatment will include an initial visit to the staff neurologist and further multidisciplinary treatment as per his decision (the team includes a psychologist and a physical therapist).
Study: NCT04090138

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Setria performance blend
Description: Oral capsules
Study: NCT00209222

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: chemotherapy: R-DHAP
Description: immuno-chemotherapy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: chemotherapy: Dexa-BEAM
Description: chemotherapy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: stem cell harvest
Description: procedure

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: stem cell harvest
Description: procedure

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: total body irradiation
Description: radiation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: total body irradiation
Description: radiation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: high-dose chemotherapy: Cyclophosphamide
Description: chemotherapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: high-dose chemotherapy: Ara-C /Melphalan
Description: chemotherapy
Study: NCT04090138

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral capsules
Study: NCT04186702

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: INTRAVITREAL RANIBIZUMAB INJECTION
Description: interventions involving RANIBIZUMAB INJECTION 0.5 mg (0.05 mL of 10 mg/mL solution)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: INTRAVITREAL RANIBIZUMAB INJECTION
Description: interventions involving RANIBIZUMAB INJECTION 0.5 mg (0.05 mL of 10 mg/mL solution)
Study: NCT00703794

Intervention type: DEVICE
Intervention: The AXIUM Progressive Coil System
Description: Embolization of aneurysm
Study: NCT01978470

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: External Trigeminal Nerve Stimulation (eTNS)
Description: External stimulation of the trigeminal nerve.
Study: NCT00828074

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Dose level 1 = 200 mg by mouth two times a day on days 1-28 of a 28 day cycle. Dose level 2 = 200 mg by mouth two times a day on days 1-28 of a 28 day cycle. Dose level 3 = 200 mg by mouth in the am and 400 mg by mouth in the pm on days 1-28 of a 28 day cycle. Dose level 4 = 400 mg by mouth two times a day on days 1-28 of a 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine ditartrate
Description: Dose level 1 = 20 mg/m2 IV weekly on days 1, 8, and 15 of a 28 day cycle. Dose level 2 = 25 mg/m2 IV weekly on days 1, 8, and 15 of a 28 day cycle. Dose level 3 = 25 mg/m2 IV weekly on days 1, 8, and 15 of a 28 day cycle. Dose level 4 = 25 mg/m2 IV weekly on days 1, 8, and 15 of a 28 day cycle.
Study: NCT02883075

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Supine position
Description: Spinal anesthesia in sitting position then 2 minutes in Supine position after spinal anesthetic administration

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Right lateral position
Description: Spinal anesthesia in sitting position then 2 minutes in the right lateral position after spinal anesthetic administration

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Left lateral position
Description: Spinal anesthesia in sitting position then 2 minutes in the left lateral position after spinal anesthetic administration
Study: NCT04392388

Intervention type: BIOLOGICAL
Intervention: Non applicable
Description: to collect data from questionnaires and to collect serological samples
Study: NCT01543763

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PZP115891, PCI-24781
Description: PCI-24781: oral, 30 to 75 mg/m2 b.i.d. Cycle 1, Days -7 to -4 and Cycle 1 and ongoing - Days 1-5, 8-12, 15-19~PZP115891: oral, 400 - 800 mg qd 28 days per cycle
Study: NCT02572596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhTPO
Description: rhTPO was administered 15 000 U/d once daily by subcutaneous injection from day 5-7 after chemotherapy and until the stem cell collection was completed.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CTX
Description: CTX 2.5/m2 for 2 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTX
Description: CTX 2.5/m2 for 2 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: -CSF
Description: 10 ug/kg/d of G-CSFwas administered from the WBC was lower than 1×10\^9/L following bejing of chemotherapy or no later than day 7after chemotherapy. G-CSF was subcutaneously administered once daily until the stem cell collection was completed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: -CSF
Description: 10 ug/kg/d of G-CSFwas administered from the WBC was lower than 1×10\^9/L following bejing of chemotherapy or no later than day 7after chemotherapy. G-CSF was subcutaneously administered once daily until the stem cell collection was completed.
Study: NCT05749770

Intervention type: OTHER
Intervention: blood testing
Description: blood testing for basal hormones and markers of inflammation

Intervention type: OTHER
Intervention: blood testing
Description: blood testing for basal hormones and markers of inflammation
Study: NCT01264237

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoricoxib
Description: 90mg Tablet QD at 10:00a.m.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One tablet QD at 10:00a.m.
Study: NCT04064242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CMK389
Description: single i.v. dose every 4 weeks
Study: NCT02150083

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: OR retrograde fill
Study: NCT04064242

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single i.v. dose every 4 weeks
Study: NCT03624543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CFI-400945
Description: 32mg; 28 day cycles; Cycle 1: Days 1-7 then 15-21 Cycle 2 onward: Daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CFI-400945
Description: 32mg; 28 day cycles; Cycle 1: Days 1-7 then 15-21 Cycle 2 onward: Daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CFI-400945
Description: 32mg; 28 day cycles; Cycle 1: Days 1-7 then 15-21 Cycle 2 onward: Daily
Study: NCT01958216

Intervention type: OTHER
Group type: OTHER
Intervention: Intravenous injection of deuterated cholesterol diluted in intralipid 20%
Description: At day 0, bile diverted patients will receive an intravenous injection of deuterated cholesterol diluted in intralipid 20%. The plasma, biliary and fecal content of deuterated cholesterol will be measured, by mass spectrometry, at 24, 48 and 72 hours after the initial input.
Study: NCT02361060

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine
Description: 40mcg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: 4mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atropine
Description: 10 mcg/kg
Study: NCT03684720

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Discover followed by direct instruction [DD]
Description: The intervention group will be taught suturing using the principles of guided-discovery-learning. In its simplest form, this means allowing the participants to practice placing a simple interrupted suture using the materials needed, as well as a picture of a finished suture. They must then draw from their own learning experiences, as well as discover for themselves how to do it. After a discovery period, an instructor will then teach them, how to place a simple interrupted suture, and will them guide them, as they begin to practice again.